Symbiotec Pharmalab Limited has announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a total income of ₹2,800.40 million for the quarter, with a net profit of ₹517.18 million. The consolidated financial results were approved by the Board of Directors on November 5, 2026, and have undergone a limited review by statutory auditors.
Symbiotec Pharmalab Announces Q2 FY27 Financial Results
Symbiotec Pharmalab Limited has officially disclosed its unaudited consolidated financial results for the second quarter and the first half of the financial year ending September 30, 2026. The announcement, made on November 05, 2026, highlights the company’s financial performance during the specified periods.
Quarterly Financial Highlights
For the quarter ended September 30, 2026, Symbiotec Pharmalab reported a total income of ₹2,800.40 million. This comprised revenue from operations amounting to ₹2,799.28 million and other income of ₹1.12 million. Total expenses for the quarter stood at ₹2,159.96 million. Consequently, the profit before tax was ₹640.44 million. After accounting for income tax expenses of ₹123.26 million, the company posted a net profit for the quarter of ₹517.18 million. The total comprehensive income for the quarter was ₹524.05 million.
Half-Yearly Financial Performance
In the half-year ended September 30, 2026, the consolidated total income reached ₹4,985.28 million, with revenue from operations at ₹4,980.78 million. Total expenses for the period were ₹4,169.52 million, leading to a profit before tax of ₹815.76 million. The income tax expense for the half-year was ₹157.97 million, resulting in a net profit of ₹657.79 million. The total comprehensive income for the half-year stood at ₹665.32 million.
Key Financial Metrics
The earnings per share (EPS) for the quarter ended September 30, 2026, was ₹8.20 (basic) and ₹8.20 (diluted). For the half-year ended September 30, 2026, the basic EPS was ₹10.44 and diluted EPS was also ₹10.44.
Auditor’s Review
The financial results were reviewed by SRBC & CO LLP, Chartered Accountants, who issued an unmodified report. The Board of Directors approved these results on November 5, 2026.
Trading Window Closure
The trading window for dealing in the company’s securities will remain closed for 48 hours from the announcement of these results.
Information Availability
The financial information is also available on the company’s website at https://investor.symbiotec.com/financials?tab=results.
Source: BSE
